New drug combo aims to wipe out lung cancer before surgery
NCT ID NCT07493980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (JSKN016, toripalimab, and carboplatin) given before surgery to people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the treatment can completely or mostly eliminate the tumor before the operation. About 54 adults will take part, and the study will track how well the cancer responds and how long people live without the disease coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy before lung surgery shows promise in early trial
- New combo therapy aims to shrink lung tumors before surgery
- Chemo-Free combo shows promise in lung cancer trial
- Can a soy compound shield lungs from radiation damage?
- Can a tailored home exercise program help lung cancer patients? new study aims to find out